BRAF and colorectal carcinoma: In conclusion, our results provide evidence that co-treatment with 3-BP and cetuximab induced synergistic antiproliferative effects by triggering apoptosis and autophagy-dependent ferroptosis in CRC cells that carry KRAF/BRAF mutations or have developed acquired resistance.